Pacira BioSciences Inc

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

PCRX$36.49+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	March 31,2025	December 31,2024
ASSETS
Current assets:
Cash and cash equivalents	$283,610	$276,774
Short-term available-for-sale investments	210,016	207,841
Accounts receivable, net	104,745	113,304
Inventories, net	133,754	125,282
Prepaid expenses and other current assets	27,837	21,929
Total current assets	759,962	745,130
Fixed assets, net	164,451	167,169
Right-of-use assets, net	48,728	49,222
Goodwill	21,520	—
Intangible assets, net	434,969	425,970
Deferred tax assets	129,008	130,376
Investments and other assets	28,031	35,649
Total assets	$1,586,669	$1,553,516
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$23,172	$19,133
Accrued expenses	80,069	80,124
Lease liabilities	9,405	8,887
Current portion of convertible senior notes, net	202,086	201,776
Total current liabilities	314,732	309,920
Convertible senior notes, net	279,801	279,334
Long-term debt, net	101,489	104,211
Lease liabilities	43,678	44,645
Contingent consideration	17,566	20,241
Deferred tax liabilities	6,996	—
Other liabilities	23,866	16,817
Total liabilities	788,128	775,168
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at March 31, 2025 and December 31, 2024	—	—
Common stock, par value $0.001; 250,000,000 shares authorized; 47,120,647 shares issued and 46,283,407 shares outstanding at March 31, 2025 and 47,077,844 shares issued and 46,240,604 shares outstanding at December 31, 2024	47	47
Treasury stock, at cost, 837,240 shares at March 31, 2025 and December 31, 2024, inclusive of excise tax	(25,121)	(25,121)
Additional paid-in capital	1,023,808	1,009,435
Accumulated deficit	(201,544)	(206,356)
Accumulated other comprehensive income	1,351	343
Total stockholders’ equity	798,541	778,348
Total liabilities and stockholders’ equity	$1,586,669	$1,553,516

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.